ATLX-1088 / Alchemab Therap - LARVOL DELTA

RESILIENCE-ASSOCIATED CD33 ANTIBODY ATLX-1088, A POTENT STIMULATOR OF MICROGLIAL PHAGOCYTOSIS (ADPD 2024) - "Overall, these data suggest that ATLX-1088 has potential as a therapeutic candidate for reversal of microglial dysfunction in Alzheimer's Disease and potentially other neurodegenerative conditions."

Alzheimer's Disease • CNS Disorders • Dementia • CD33

Human-derived CD33 antibody ATLX-1088, a potent stimulator of microglial pharmacology (Neuroscience 2023) - "From a development perspective, this antibody showed high levels of monomer, good thermostability, and minimal loss of binding under forced degradation conditions. Overall, these data suggest that ATLX-1088 has high potential as a therapeutic candidate for the reversal of microglial dysfunction in Alzheimer's Disease and potentially other neurodegenerative conditions."

Alzheimer's Disease • CNS Disorders • Dementia • CD33

Alchemab Therapeutics unveils Alzheimer’s candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium (PRNewswire) - "Alchemab Therapeutics...today announced that it unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer's candidate, at the Antibody Industrial Symposium in Tours, France, 22-23 June 2023."

Preclinical • Alzheimer's Disease • CNS Disorders